Blog

Ben Gorman

Ben Gorman is a Venture Partner at F-Prime, where he focuses on early-stage investments in enterprise software and frontier technologies. Prior to joining F-Prime, he was a managing consultant at IBM, providing internal strategy and analytics consulting to IBM’s business units and geographies. The primary focus of his work was transforming the company’s go-to-market to better leverage data, analytics, and technology. Over the course of his tenure, he gained experience on the ground in 10 countries across 4 continents.

Ben is a graduate of Carnegie Mellon University, where he received degrees in Economics and Statistics.

Gaurav Tuli

Gaurav is a Partner at F-Prime where he focuses on enterprise technology investing. He has led F-Prime investments in Threat Stack (acquired by F5 Networks), RiskRecon (acquired by Mastercard), Protenus (acquired by Bluesight), Risklens (acquired by Safe Security), Lighthouse, Canary Technologies, Funnel, Warmly, Deal Engine, and many others. Prior to F-Prime, Gaurav was a Principal at F-Prime’s sister fund, Eight Roads Ventures Europe, based in London, where he invested in European software and online services businesses and served on the boards of Appsflyer and Neo4j. Previously, Gaurav was a product portfolio manager at EMC’s largest business unit, Symmetrix. Gaurav was a computer scientist by training and spent the early parts of his career at Credit Suisse and McKinsey and Company.

Gaurav attended MIT for his bachelors and masters degrees in computer science, as well as his MBA.

Sanjay Aggarwal

Sanjay Aggarwal is a Venture Partner focused on frontier technology and enterprise software investment opportunities. Prior to joining F-Prime, Sanjay was CEO of Unicel Technologies, an India-focused mobile messaging company. Sanjay scaled Unicel to become a leader in the Indian market and successfully exited the business to Karix Mobile.

Earlier in his career, Sanjay worked at Devonshire Investors (the private equity group of Fidelity Investments), McKinsey and Company in their US and India offices, and at Berkeley Process Control (acquired by Moog Inc), where he built machine automation systems. Sanjay holds a B.S. in Mechanical Engineering from MIT, an M.S. in Mechanical Engineering from UC Berkeley, and an M.B.A. from the MIT Sloan School of Management.

Chong Xu, PhD

Chong Xu is a Partner at F-Prime. He focuses primarily on biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of AlphaGen Tx, Pediatrix, Skyline Tx, K36 Tx, and RareStone Group. Other companies Chong holds or has held board positions also include OnCusp Tx, Remunix, Shinobi Tx, Sironax, Semma Tx, Adagene, Innovent, etc. Prior to joining F-Prime in 2015, Chong was a management consultant at McKinsey and Company, a hedge fund healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a PhD in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

Jessica Alston, PhD

Jessica is a Partner at F-Prime and focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2015, Jessica was an engagement manager in McKinsey and Company’s Boston office, where she focused on pharmaceuticals and medical products and advised companies across a range of strategic, organizational, and operational topics. She began her career at MIT Lincoln Laboratory in the Biodefense Systems group, where she worked on developing novel techniques for the detection of biological agents.

Jessica holds a PhD in genetics from Harvard University and received her BS in biology from Duke University.

Stacie Weninger, PhD

Stacie Weninger, PhD is the President of FBRI and a Venture Partner with F-Prime Capital. Dr. Weninger focuses on advancing neuroscience research and early-stage therapeutics through strategic collaboration, investment, and advisory roles. Through these activities, she contributes to the translation of early discoveries into novel therapeutics and helps to build innovative neuroscience companies.

She currently serves as CEO and Chairman of the Board of Directors at Rugen Therapeutics, and serves on the Boards of Aratome, Atalanta, Engrail, and Tenvie Therapeutics. She was a founding member of the Board of Directors at Denali Therapeutics (NASDAQ: DNLI) and Neumora Therapeutics (NASDAQ: NMRA) and has held Board roles at companies including Annexon Biosciences (NASDAQ: ANNX), BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix (acquired by Bruker Corporation), and Sironax.

In addition to her work in biotech investing, Dr. Weninger serves in leadership and advisory roles for several different organizations, including the Board of Target ALS, the Governing Board of the Michael J Fox Foundation Targets to Therapeutics Initiative, the External Advisory Board of Boston Children’s Hospital’s Rosamund Stone Zander Translational Neuroscience Center. Dr. Weninger also chairs the Collaboration for Alzheimer’s Prevention, which seeks to share learnings and best practices to facilitate clinical trials in early-stage Alzheimer’s disease. She is also a member of the Scientific Advisory Boards of Denali Therapeutics, the Breuer Foundation, Harvard Blavatnik Biomedical Accelerator Fund, the Indian Institute of Science’s Centre for Brain Research, and the MIT’s Yang-Tan Center for Molecular Therapeutics, among others. Dr. Weninger was previously the President of Alzforum for over a decade and continues as a special advisor to the site.

Prior to joining F-Prime, Dr. Weninger was Senior Director of Science Programs at the Fidelity Foundations, where she oversaw biomedical research funding initiatives. Earlier in her career, she served as Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University and was a Senior Scientific Editor at Neuron (Cell Press). Dr. Weninger began her career as a postdoctoral research fellow in Dr. Bruce Yankner’s lab at Boston Children’s Hospital and Harvard Medical School.

Dr. Weninger received her PhD in neuroscience from Harvard University as a Howard Hughes Medical Institute predoctoral fellow and earned a BS in chemistry with highest honors from the University of North Carolina at Chapel Hill.

Kevin Chu

Kevin Chu joined F-Prime in 2014 and is currently a Principal on the healthcare investment team based in San Francisco. Prior to F-Prime, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy.

At F-Prime, Kevin focuses primarily on investments in therapeutics, medical devices, and life science tools companies. He was a member of the founding team at Shinobi Therapeutics, led the fund’s investments in Apreo Health, Amber Therapeutics, Cadence Neuroscience and was involved with several legacy fund investments including Innovent Biologics (1801.HK), Semma Therapeutics (acquired by Vertex), Modis Therapeutics (acquired by Zogenix), Farapulse (acquired by Boston Scientific), Cytek Biosciences (NASDAQ: CTKB), and Sipai Health Technology (0314.HK). He also works closely with the Eight Roads Ventures China team to manage F-Prime’s healthcare investment efforts in China.

Kevin holds a B.S.E. from the University of Pennsylvania where he studied Bioengineering and Engineering Entrepreneurship.

Shervin Ghaemmaghami

Shervin joined F-Prime in 2012 to help start the technology fund. He focuses on startups building tools for scientists (e.g., Benchling, BenchSci, Albert), engineers (e.g., ReadMe, Codeship – acquired by CloudBees, Cloudant – acquired by IBM), and modern fintech infrastructure (e.g., Recurly – acquired by Accel-KKR).

Shervin began his venture career at Polaris Partners and previously held operating roles at The Atlantic and several MIT spinouts. He also worked for McKinsey & Company in the U.S., Europe, Asia and Middle East. Shervin was born and raised in London, and has undergraduate and master’s degrees in Engineering from both the University of Cambridge and MIT.

David Jegen

David is Managing Partner of F-Prime’s Tech Fund. He invests at the intersection of fintech and enterprise software, and has led investments in Flywire (NASDAQ: FLYW), Toast (NYSE: TOST), Snapdocs, Kensho (acquired by S&P Global), FutureAdvisor (acquired by BlackRock), Quovo (acquired by Plaid), EVEN Financial (acquired by MoneyLion), Vendr, 1upHealth, Notabene, TradeBlock (acquired by CoinDesk), Papaya Payments, Unison, Tradier, Axoni, Parrot Software, Canoe Intelligence, and Cloudant (acquired by IBM). David was co-founder of Sensoria and VP of Product Strategy at Into Networks, an F-Prime Capital-backed company. David was also a senior executive at Cisco Systems and held early positions with J.P. Morgan and BCG.

David graduated from Harvard Law School and earned degrees in economics and accounting from Indiana University. David is passionate about Fintech Sandbox, a nonprofit he co-founded in 2015 to serve fintech entrepreneurs by aggregating data and infrastructure for free during a startup’s development phase. Fintech Sandbox has supported 200+ startups and fostered a vibrant organization with more than 5,000 community members. He also serves on the Boards of Artists for Humanity and the Mass Fintech Hub. He is the father of two lovely teens with whom he shares the inspiration that comes from living with his wife Cindy and her poetry, stories, and pursuit of social justice.

Carl Byers

Carl Byers brings significant operating experience in healthcare IT to his role as Partner. He was on the founding team at athenahealth, Inc. (Nasdaq: ATHN), where he served as Chief Financial Officer from 1997 to 2010. Carl was responsible for the company’s finance, legal and corporate technology teams and served as a key advisor to the CEO. When athenahealth was a private company, he built the company’s financial systems and led seven rounds of equity and subordinated debt financing. Carl led athenahealth’s 2007 Initial Public Offering, which the Wall Street Journal named as the year’s most successful. In his tenure, he also held various operational roles at different times. Prior to the founding of athenahealth, Carl was a Senior Consultant in Booz, Allen & Hamilton’s New York office, where he worked in the financial services and health insurance industries. Carl teaches finance at Harvard’s Chan School of Public Health where he is an Adjunct Lecturer on Health Policy and Management. He was appointed by Governor Charlie Baker to the Massachusetts Digital Health Council.

Carl holds a B.A. from Wesleyan and is a graduate of the Harvard Kennedy School’s Mid-Career Masters in Public Administration program.